Febuxostat

1 Becker M A, Kisicki J, Khosravan R. et al . Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004; 23 1111-1116
2 Becker M A, Schumacher H R, Espinoza L R. et al . The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12 R63
3 Becker M A, Schumacher Jr H R, Wortmann R L. et al . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353 2450-2461
4 Becker M A, Schumacher Jr H R, Wortmann R L. et al . Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005; 52 916-923
5 Becker M A, Schumacher H R, MacDonald P A. et al . Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009; 36 1273-1282
6 EMA .Adenuric. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000777/WC500021812.pdf Stand Mai 2008
7 Emmerson B T. The management of gout. N Engl J Med. 1996; 334 445-451
8 Fachinformation. Allopurinol. Stand April 2009.
9 Fachinformation. Adenuric, Febuxostat. Stand Dez. 2009.
10 FDA/CDER .Med. Review Febuxostat. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000_MedR_P1.pdf bis http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000_MedR_P5.pdf Stand Dez. 2008
11 Lee H Y, Ariyasinghe J T, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?. Singapore Med J. 2008; 49 384-387
12 Moreland L W. Febuxostat – treatment for hyperuricemia and gout?. N Engl J Med. 2005; 353 2505-2507
13 NICE .Febuxostat for the management of hyperuricaemia in people with gout. http://www.nice.org.uk/nicemedia/pdf/TA164Guidance.pdf Dez. 2008
14 Okamoto K, Eger B T, Nishino T. et al . An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003; 278 1848-1855
15 Okamoto K, Matsumoto K, Hille R. et al . The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci U S A. 2004; 101 7931-7936
16 Okamoto K, Nishino T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. J Nippon Med Sch. 2008; 75 2-3
17 Reinders M K, Haagsma C, Jansen T L. et al . A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300 – 600 mg/day versus benzbromarone 100 – 200 mg/day in patients with gout. Ann Rheum Dis. 2009; 68 892-897
18 Schumacher Jr H R. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs. 2005; 14 893-903
19 Schumacher Jr H R, Becker M A, Lloyd E. et al . Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009; 48 188-194
20 Schumacher Jr H R, Becker M A, Wortmann R L. et al . Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59 1540-1548
21 Takeda .US-amerikanische Produktinformation Uloric (Febuxostat). Stand Feb. 2009.
22 Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010; 6 30-38
23 Yu K H. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov. 2007; 1 69-75

Prof. Dr. med. Ali El-Armouche

Abteilung Pharmakologie
Universitätsmedizin Göttingen

Robert-Koch-Str. 40

37075 Göttingen

Phone: 0551/39-22602

Fax: 0551/39-5699

Email: ali.el-armouche@med.uni-goettingen.de